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Abstract
The new Vaccine technologies against transmissible 
and non-transmissible diseases, such as cancer, have 
had an impact on international public health. The human 
papillomavirus (HPV) vaccine is used on a large scale 
in immunization programs in more than 58 countries, 
with resultant efficacy and safety for precursor lesions 
of cervical cancer, in addition to anogenital lesions. 
After the introduction of quadrivalent HPV vaccine 
(6,11,16 and 18) in Brazil in 2014, monitoring the 
vaccination coverage and the development of HPV 
prevalence incidence of cervical abnormalities and 
precancerous lesions must be observed, as well as 
morbidity and mortality trends from in situ and invasive 
cancer. Encouraging information, counseling and 
continuing education is recommended as a strategy to 
broaden vaccine acceptance in order to sediment its 
implementation and ensure effectiveness in reducing 
new cases of cervical cancer in the future. 
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Cervical cancer contributes to morbidity 
and mortality among women in Latin America; 
prevention, with early detection and health 
promotion essential in addressing the problem1,2. 
The estimated 16,340 new cases make cervical 
cancer the second most common neoplasm in the 
Northeast region3. The persistence of new cases 
and the high incidence in certain regions of the 
country are related to HPV (human papillomavirus) 
infection with high oncogenic risk (ability to cause 
pre-malignant lesions, in situ and invasive cancer), 
persistence of infection; contributing factors include 
low socioeconomic level, other genital infections, 
immunosuppression and genetic causes. The 
prevalence of high-risk oncogenic HPV in specific 
territories and populations combine with the ethnic 
or racial differences that exist in our country2-4. 
Research to identify the particulars in each territory 
are important for HPV prevention, early detection 
of precursor lesions and actions in health promotion 
as continuing education for professionals and 
health education in the self-care of the population 
in general and the vulnerable3,4.
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Since 2014, the National Immunization 
Program of the Ministry of Health (PNI-MS) has 
provided the quadrivalent HPV vaccine (6,11,16 
and 18) for girls aged 9-14 years, including women 
living with HIV up to 26 years; 12 and 13 year-
old boys and 9 to 26 year-old boys and men with 
HIV under medical guidance have also been added4. 
The primary prevention represented by condom use 
and a quadrivalent vaccine for HPV, as well as the 
advent of new vaccines (such as the “nonavalente” 
vaccine) represent a technological advance in health 
and a gain for women’s health in the short and long 
term5.
Countries that have adopted the quadrivalent 
vaccine have reported reduction of precursor lesions 
from 60-80%, with rates of 100% in populations 
vaccinated with the quadrivalent vaccine (6, 11, 16 
and 18) for cases of genital warts5-7.
The optimal timing of vaccination for HPV 
is recommended prior to the first sexual contact of 
an individual. Vaccine efficacy in men and women 
suggests that immunization is more effective among 
individuals who have not been infected with HPV 
and reduces the morbidity of young women related 
to precursor lesions and cancer in situ8.
However, the vaccination coverage in the 
target population of adolescents before their initial 
sexual contact since the implementation of vaccine 
in the larger population, with percentages below 
80% among adolescents in specific territories. 
That is below the expected and recommended by 
the WHO for the first and second dose ensuring the 
herd effect (benefits of the application of vaccines 
received by uninoculated people)9.
Understanding the factors that affect the HPV 
vaccination decision-making is critical if health 
promotion interventions are to be developed and 
address doubts, myths and fears of acceptance in 
population groups least likely to receive the HPV 
vaccine9,10.
Factors affecting the adequate vaccination 
coverage in a given population are examined 
at different socio-territorial levels that include 
political, community, organization, interpersonal 
(parent-child relationship), and intrapersonal 
(professional) relations10. In a recent review, Ferrer 
et al.10, emphasized political factors, parents and 
guardians’ decision, as well as the knowledge and 
counseling of health professionals as the main 
reasons in decision-making to obtain the vaccine for 
HPV. Still, these decisions are influenced by safety 
and efficacy of the vaccine; social norms and values 
related to sexual activity; confidence in vaccination 
programs and caregivers9,10. In our universal health 
system, individual financial limitations are not a 
significant influence in the decision-making since 
the vaccine is supplied to the target population 
without cost11.
In health facilities, health professionals’ 
limited knowledge and skills in providing HPV 
vaccine could restrict a young woman’s access 
to the vaccine regardless of her own beliefs and 
preferences12. Health professionals represent, 
in some studies, the main providers of advice 
on the vaccine. The relationship between the 
practitioner and the decision-maker requires clear, 
accessible and sometimes culturally appropriate 
communication and information about the HPV 
vaccination program12,13.
Parents may decide not to allow their daughters 
to be vaccinated, based on cultural or religious 
perceptions, and the unsubstantiated correlation 
of the vaccine facilitating early sexual activity12,13. 
Identification of HPV vaccine knowledge gaps and 
acceptance barriers among adolescents, parents/
guardians and health professionals are necessary 
to develop targeted education programs for the lay 
population and continuing education in the work 
process of health professionals13,14. 
Although young women are a critical part of the 
HPV vaccination program, the underrepresentation 
of their opinions in the qualitative literature should 
be considered in future research13. Health promotion 
activities should focus on the tripod of adolescents, 
parents/guardians and health care professionals to 
ensure adequate vaccine coverage and ensure the 
promising results of the vaccine.
The Journal of Human Grown Development 
(JHGD) brings the theme of health promotion in the 
scientific dissemination of articles and discusses 
necessary changes in the health-disease process, as 
in the study of Conception of the Right to Health of 
Mid-Level Technical Professionals of the Unified 
Health System In Brazil. The article reports on 
the biological model focused on the disease and 
medicalization as elements that still dominate in the 
Unified Health System policy15.
The permanent commitment of the journal 
JHGD to publish themes focused on healthy 
development inserted in the child and adolescent 
life cycle as the association of the prevalence 
of exposure to fluoride in the nails of children’s 
hands with dental fluorosis16-18; between delayed 
neuropsychomotor development and infants of 
street drug users19 and the association of adequate 
growth with lipid profiles20. 
The journal JHGD presents the importance 
of the concept of reproductive planning and 
preconception planning as a health promotion for 
children, as well as for the current situation of 
teenage pregnancy and the association with arterial 
hypertension21,22. Sexual and reproductive rights are 
DOI: http://dx.doi.org/10.7322/jhgd.143887
HPV vaccine: knowledge and acceptance to ensure effectiveness J Hum Growth Dev. 2018; 28(1):5-8
7
considered in the cited article on the repercussions 
of Zika virus during pregnancy23. In the field of 
public health, the journal discloses the importance 
of identifying risk to provide quality care for 
chronic diseases24 and non-communicable diseases 
as well as the indiscriminate use of antibiotics25.
The perception and involvement of children 
and adolescents in clinical research, consent and 
assent and shared decision-making must be present 
in the development and planning of actions in health 
promotion for this population.
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Resumo
As novas tecnologias em vacina contra doenças transmissíveis e não transmissíveis 
como o câncer, tiveram impacto na saúde pública internacional, especificamente a 
vacina para o papiloma vírus humano (HPV) utilizada em larga escala nos programas de 
imunização em mais de 58 países, com resultados de eficácia e segurança para lesões 
precursoras do câncer de colo do útero além de lesões anogenitais. Após a introdução 
em território Nacional da vacina quadrivalente para o HPV (6,11,16 e 18) desde 2014, 
ressalta-se a importância do monitoramento da cobertura vacinal e o desenvolvimento 
de estudos de prevalência de HPV em logo prazo, de incidência de anormalidades 
cervicais e lesões pré-cancerosas bem como de tendência de morbimortalidade por 
câncer in situ e invasivo. O incentivo às informações, aconselhamento e educação 
continuada é recomendado como uma estratégia para ampliar a aceitação da vacina 
a fim de sedimentar sua implantação e assegurar a eficácia na redução dos novos 
casos de câncer de colo do útero para o futuro.
Palavras-chave: HPV, vacinas contra papillomavirus, vacina quadrivalente 
recombinante contra HPV tipos 6, 11, 16, 18, neoplasias do colo do útero.
